Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Therapeutic Innovation & Regulatory Science
|
July 6, 2021
Radiologists and Clinical Trials: Part 1 The Truth About Reader Disagreements
Annette M Schmid, David L Raunig, Colin G Miller, et al.
Hepatology Communications
|
January 12, 2023
Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury
Colin T Shearn, Aimee L Anderson, Colin G Miller, et al.
Seminars in Arthritis and Rheumatism
|
June 19, 2017
Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment
Frank W Roemer, Colin G Miller, Christine R West, et al.
Plos One
|
November 15, 2022
The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease
Colin T Shearn, Aimee L Anderson, Michael W Devereux, et al.
Journal of Drug Assessment
|
August 19, 2016
Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics
Lorraine A Fitzpatrick, John P Bilezikian, Margaret Wooddell, et al.
Annals of the Rheumatic Diseases
|
November 13, 2012
A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
Marie-Pierre Hellio le Graverand, Ray S Clemmer, Patricia Redifer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 3, 2021
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Irene Virgolini, Shadfar Bahri, Andreas Kjaer, et al.
Antioxidants (Basel, Switzerland)
|
March 6, 2021
Supplemental Ascorbate Diminishes DNA Damage Yet Depletes Glutathione and Increases Acute Liver Failure in a Mouse Model of Hepatic Antioxidant System Disruption
Colin G Miller, Jean A Kundert, Justin R Prigge, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry
|
April 8, 2016
Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint
Colin G Miller, Cesar C Bogado, Antonio J Nino, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 2, 2013
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus
John P Bilezikian, Robert G Josse, Richard Eastell, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Therapeutic Innovation & Regulatory Science
|
July 6, 2021
Radiologists and Clinical Trials: Part 1 The Truth About Reader Disagreements
Annette M Schmid, David L Raunig, Colin G Miller, et al.
Hepatology Communications
|
January 12, 2023
Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury
Colin T Shearn, Aimee L Anderson, Colin G Miller, et al.
Seminars in Arthritis and Rheumatism
|
June 19, 2017
Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment
Frank W Roemer, Colin G Miller, Christine R West, et al.
Plos One
|
November 15, 2022
The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease
Colin T Shearn, Aimee L Anderson, Michael W Devereux, et al.
Journal of Drug Assessment
|
August 19, 2016
Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics
Lorraine A Fitzpatrick, John P Bilezikian, Margaret Wooddell, et al.
Annals of the Rheumatic Diseases
|
November 13, 2012
A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
Marie-Pierre Hellio le Graverand, Ray S Clemmer, Patricia Redifer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 3, 2021
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Irene Virgolini, Shadfar Bahri, Andreas Kjaer, et al.
Antioxidants (Basel, Switzerland)
|
March 6, 2021
Supplemental Ascorbate Diminishes DNA Damage Yet Depletes Glutathione and Increases Acute Liver Failure in a Mouse Model of Hepatic Antioxidant System Disruption
Colin G Miller, Jean A Kundert, Justin R Prigge, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry
|
April 8, 2016
Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint
Colin G Miller, Cesar C Bogado, Antonio J Nino, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 2, 2013
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus
John P Bilezikian, Robert G Josse, Richard Eastell, et al.
Page
of 3